FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women

European Journal of Endocrinology

Volumn 164, Issue 4, 2011, Pages 539-547

  Terra, Ximena ^a,b   Quintero, Yunuen ^a   Auguet, Teresa ^a,b   Porras, Jose Antonio ^a,b   Hernández, Mercé ^c   Sabench, Fátima ^c   Aguilar, Carmen ^a,b   Luna, Anna María ^a   Castillo, Daniel Del ^c   Richart, Cristobal ^a,b  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b Grup d'Estudi de Malalties Metaboliques Asociades A Insul Resist (GEMMAIR) 2009 SGR 959 (AGAUR)   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN 4; GLUCOSE; INSULIN; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; RESISTIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADIPOSE TISSUE; ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MORBID OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN; SUBCUTANEOUS TISSUE; ABDOMINAL FAT; CLINICAL ARTICLE; GENE EXPRESSION; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; INFLAMMATION; INTRAABDOMINAL FAT; METABOLIC PARAMETERS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SUBCUTANEOUS FAT;

ADIPONECTIN; ADULT; C-REACTIVE PROTEIN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INFLAMMATION; LEPTIN; METABOLIC SYNDROME X; OBESITY, MORBID; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 79953249421     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-1195     Document Type: Article

References (33)

1. Berg AH & Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005 96 939-949. (doi:10.1161/01.RES.0000163635.62927.34)
2. Blüher M. Adipose tissue dysfunction in obesity. Experimental and Clinical Endocrinology and Diabetes 2009 117 241-250. (doi:10.1055/s-0029- 1192044)
3. Ahima RS & Osei SY. Adipokines in obesity. Frontiers of Hormone Research 2008 36 182-197. (doi:10.1159/000115365)
4. Khuseyinova N & Koenig W. Biomarkers of outcome from cardiovascular disease. Current Opinion in Critical Care 2006 12 412-419. (doi:10.1097/01.ccx. 0000244119.16377.75)
5. Krušinová E & Pelikánová T. Fatty acid binding proteins in adipose tissue: a promising link between metabolic syndrome and atherosclerosis? Diabetes Research and Clinical Practice 2008 82 (Supplement 2) S127-S134. (doi:10.1016/j.diabres.2008.09.023)
6. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NMS, Wong WK & Lam KSL. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clinical Chemistry 2006 52 405-413. (doi:10.1373/clinchem.2005.062463)
7. Furuhashi M, Fucho R, Görgün CZ, Tuncman G, Cao H & Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. Journal of Clinical Investigation 2008 118 2640-2650. (doi:10.1172/ JCI34750)
8. Karakas SE, Almario RU & Kim K. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism 2009 58 1002-1007. (doi:10.1016/j.metabol.2009.02.024)
9. Chmurzyñska A. The multigene familyof fatty acid-binding proteins (FABPs): function, structure and polymorphism. Journal of Applied Genetics 2006 47 39-48. (doi:10.1007/BF03194597)
10. Zimmerman AW & Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cellular and Molecular Life Sciences 2002 59 1096-1116. (doi:10.1007/s00018-002-8490-y)
11. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA & Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007 447 959-965. (doi:10.1038/ nature05844)
12. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE & Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996 274 1377-1379. (doi:10.1126/science.274.5291.1377)
13. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S & Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000 141 3388-3396. (doi:10.1210/en.141.9.3388)
14. Coe NR, Simpson MA & Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. Journal of Lipid Research 1999 40 967-972. (Pubitemid 29220539)
15. Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA & Hotamisligil GS. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999 48 1987-1994. (doi:10.2337/diabetes.48.10.1987)
16. Baar RA, Dingfelder CS, Smith LA, Bernlohr DA, Wu C, Lange AJ & Parks EJ. Investigation of in vivo fatty acid metabolism in AFABP/aP2-/- mice. American Journal of Physiology. Endocrinology and Metabolism 2005 288 E187-E193. (doi:10.1152/ajpendo.00256.2004)
17. Makowski L, Brittingham KC, Reynolds JM, Suttles J & Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Journal of Biological Chemistry 2005 280 12888-12895. (doi:10.1074/jbc.M413788200)
18. Hyun Koh J, Goo Shin Y, Min Nam S, Young Lee M, Hee Chung C & Yel Shin J. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care200932147-152. (doi:10.2337/dc08-1379)
19. Tso AWK, Xu A, Sham PC, Wat NMS, Wang Y, Fong CHY, Cheung BMY, Janus ED & Lam KSL. Serum adipocyte fatty acid-binding protein as a new biomarker predicting the development of type 2 diabetes. Diabetes Care 2007 30 2667-2672. (doi:10.2337/dc07-0413)
20. Xu A, Tso AWK, Cheung BMY, Wang Y, Wat NMS, Fong CHY, Yeung DCY, Janus ED, Sham PC & Lam KSL. Circulating adipocytefatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007 115 1537-1543. (doi:10.1161/CIRCULATIONAHA.106.647503)
21. Yeung DCY, Xu A, Cheung CWS, Wat NMS, Yau MH, Fong CHY, Chau MT & Lam KSL. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1796-1802. (doi:10.1161/ATVBAHA.107.146274)
22. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB & Hotamisligil GS. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. PNAS 2006 103 6970-6975. (doi:10.1073/pnas.0602178103)
23. Bonen A, Luiken JJ & Glatz JF. Regulation of fatty acid transport and membrane transporters in health and disease. Molecular and Cellular Biochemistry 2002 239 181-192. (doi:10.1023/A:1020511125085)
24. Hertzel AV, Smith LA, Berg AH, Cline GW, Shulman GI, Scherer PE & Bernlohr DA. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. American Journal of Physiology. Endocrinology and Metabolism 2006 290 E814-E823. (doi:10.1152/ajpendo.00465.2005)
25. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA & Costa F. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752. (doi:10.1161/CIRCULATIONAHA.105.169404)
26. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/diacare.27.6.1487)
27. Erbay E, Cao H & Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome. Current Atherosclerosis Reports 2007 9 222-229. (doi:10.1007/s11883-007-0023-6)
28. Stejskal D & Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? European Journal of Clinical Investigation 2006 36 621-625. (doi:10.1111/j.1365-2362.2006.01696.x)
29. Simón I, Escoté X, Vilarrasa N, Gómez J, Fernández-Real JM, Megía A, Gutiérrez C, Gallart L, Masdevall C & Vendrell J. Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity 2009 17 1124-1128.
30. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ & George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009 49 1926-1934. (doi:10.1002/hep.22896)
31. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA & Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism 2005 1 107-119. (doi:10.1016/j.cmet.2004.12.008)
32. Wang Z & Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation 2010 2010. (doi:10.1155/2010/535918)
33. Barth S, Klein P, Horbach T, Dötsch J, Rauh M, Rascher W & Knerr I. Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters. Obesity Facts 2010 3 245-251. (doi:10.1159/000319508)